Results 281 to 290 of about 103,862 (301)

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

Nature Reviews Drug Discovery, 2012
Christopher J Lord
exaly  

PARP inhibitors: pitfalls and promises

The Lancet Oncology, 2013
Jeffrey R, Infante, Howard A, Burris
openaire   +2 more sources

Missed therapeutic and prevention opportunities in women with BRCA‐mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature

Ca-A Cancer Journal for Clinicians, 2017
Paul J Hoskins, Walter H Gotlieb
exaly  

PARP inhibition: PARP1 and beyond

Nature Reviews Cancer, 2010
Michèle Rouleau, Anand G Patel, Michael J Hendzel   +2 more
exaly  

An update on PARP inhibitors—moving to the adjuvant setting

Nature Reviews Clinical Oncology, 2014
Amir Sonnenblick, Evandro de Azambuja, Hatem A Azim   +2 more
exaly  

PARP Inhibitors

2012
openaire   +1 more source

Synthetic inhibitors - PARP inhibitors

2020
openaire   +1 more source

PARP Inhibitors

2017
openaire   +1 more source

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

Nature Reviews Clinical Oncology, 2016
Angela George, Susana Banerjee
exaly  

PARP Inhibitors

2008
openaire   +1 more source